MARKET

IMUX

IMUX

Immunic Inc
NASDAQ
0.8298
-0.0003
-0.04%
Opening 15:28 07/14 EDT
OPEN
0.8400
PREV CLOSE
0.8301
HIGH
0.8439
LOW
0.8100
VOLUME
298.01K
TURNOVER
--
52 WEEK HIGH
2.110
52 WEEK LOW
0.5610
MARKET CAP
79.51M
P/E (TTM)
-0.8706
1D
5D
1M
3M
1Y
5Y
1D
Weekly Report: what happened at IMUX last week (0707-0711)?
Weekly Report · 21h ago
Immunic Inc. Announces New Stock Appreciation Rights Plan for Employees and Executives, Pending Shareholder Approval
Reuters · 3d ago
Weekly Report: what happened at IMUX last week (0630-0704)?
Weekly Report · 07/07 09:17
B.Riley Financial Remains a Buy on Immunic (IMUX)
TipRanks · 07/01 13:15
Weekly Report: what happened at IMUX last week (0623-0627)?
Weekly Report · 06/30 09:17
Immunic Reports 92% of MS Patients Had No Disability Worsening After 3 Years on Lead Oral Drug
Benzinga · 06/24 10:36
EQS-NEWS: IMMUNIC REPORTS NEW, POSITIVE LONG-TERM OPEN-LABEL EXTENSION DATA FROM PHASE 2 EMPHASIS TRIAL OF VIDOFLUDIMUS CALCIUM IN RELAPSING-REMITTING MULTIPLE SCLEROSIS
Reuters · 06/24 10:30
IMMUNIC INC - TRIAL ACHIEVED PRIMARY AND SECONDARY ENDPOINTS WITH HIGH SIGNIFICANCE
Reuters · 06/24 10:30
More
About IMUX
Immunic, Inc. is a biotechnology company developing a clinical pipeline of selective oral immunology therapies focused on treating chronic inflammatory and autoimmune diseases. The Company is engaged in pursuing clinical development of programs, which include the vidofludimus calcium (IMU-838) program, which is in Phase III clinical development for patients with relapsing multiple sclerosis (RMS), and which has shown therapeutic activity in Phase II clinical trials in patients suffering from relapsing-remitting MS, progressive MS and moderate-to-severe ulcerative colitis; the IMU-856 program, which is targeted to regenerate bowel epithelium and restore intestinal barrier function, which could potentially be applicable in numerous gastrointestinal diseases, such as celiac disease, inflammatory bowel disease, Graft-versus-Host-Disease and weight management, and the IMU-381 program, which is a molecule being developed to specifically address the needs of gastrointestinal diseases.

Webull offers Immunic Inc stock information, including NASDAQ: IMUX real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, IMUX stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading IMUX stock methods without spending real money on the virtual paper trading platform.